Last reviewed · How we verify

Mebendazole + Multivitamin — Competitive Intelligence Brief

Mebendazole + Multivitamin (Mebendazole + Multivitamin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthelmintic + nutritional supplement. Area: Infectious Disease / Parasitology.

phase 3 Anthelmintic + nutritional supplement β-tubulin (mebendazole component) Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Mebendazole + Multivitamin (Mebendazole + Multivitamin) — Johns Hopkins Bloomberg School of Public Health. Mebendazole disrupts microtubule formation in parasitic worms, causing paralysis and death, while the multivitamin component addresses nutritional deficiencies often associated with helminthic infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mebendazole + Multivitamin TARGET Mebendazole + Multivitamin Johns Hopkins Bloomberg School of Public Health phase 3 Anthelmintic + nutritional supplement β-tubulin (mebendazole component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthelmintic + nutritional supplement class)

  1. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mebendazole + Multivitamin — Competitive Intelligence Brief. https://druglandscape.com/ci/mebendazole-multivitamin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: